Locally advanced urothelial carcinoma has a poor survival despite a response to immunotherapy in approximately 25% of patients. To develop new therapies targeting other immune checkpoints, we identified increased expression of the T cell inhibitor protein, B7-H4 (VTCN1, B7S1, B7X), during tumor development of murine bladder cancer. Evaluation of B7-H4 in human bladder cancer by single-cell RNA-Seq and immune mass cytometry showed that B7-H4 is expressed by luminal tumors that are not normally responsive to PD-1 inhibitors. Additionally, overexpression B7-H4 was associated with significantly worse patient survival. In support of clinical translation, treatment of human monocyte and T cell co-cultures with a B7-H4 blocking antibody resulted in enhanced IFN-g secretion by CD4 + and CD8 + T cell. While the study of B7-H4 in mouse cancer models has been difficult using tumor cell lines, our findings show that B7-H4 expression increased at 3 months after exposure to BBN on CD11b + monocytes/macrophages and delivery of anti-B7-H4 antibody resulted in decreased tumor size and increased CD8 immune cell infiltration with increased CD8 + /IFN-g-producing T cells and a complimentary decrease in tumor infiltrating T regulatory cells (Tregs). Furthermore, treatment with a combination of anti-PD-1 and anti-B7-H4 antibodies resulted in a significant reduction in tumor stage. This data suggests that novel anti-B7-H4 antibodies maybe a viable target for bladder cancers unresponsive to PD-1 checkpoint inhibitors.
Introduction
The anti-tumor immune response is dynamic and evasion of the immune system by the tumor is hallmark of cancer. Due to the expression of neoantigens driven by tumor-derived mutations, cells of the innate and adaptive immune system are capable of mounting vigorous anti-tumor responses. Yet, many tumors are able to evade this response by upregulating checkpoint inhibitors that suppress immune activation. While CTLA-4 and PD-L1 are the most well-described checkpoint proteins, B7-H4 (B7S1, B7x, VTCN1), a B7 family member expressed on antigen presenting cells and/or tumors, and can inhibit T cell-mediated inflammatory responses. The majority of work focused on elucidating the functional immunoregulatory role of B7-H4 has involved assessment of the ability of an agonistic B7-H4-immunoglobulin fusion protein (B7-H4Ig) in the treatment of autoimmune disease, and the presence of B7-H4 expression in human cancers [as reviewed in (1)]. B7-H4 functionally decreases inflammatory CD4 + T cell directly and indirectly via B7-H4-induced increases in both the number and function of regulatory CD4 + T cells (2) (3) (4) .
However, evidence for the ability of B7-H4 blockade to decrease tumor burden is lacking due to the limited number of mouse tumors that natively express B7-H4, likely secondary to nonorthotopic placement of ex-vivo derived cell lines. However, it was reported that genetic ablation of B7-h4 (Vtcn1) in a model of liver cancer was associated with increased CD8 + infiltration of the tumor and decreased exhaustion of CD8 + T cells (5) .
In contrast to the majority of mouse tumor models, the expression level of B7-H4 protein in human ovarian cancer has been related to cancer types, cancer stage, the numbers of Tregs, and patient survival (6) (7) (8) . Additionally, more than 90% of endometrial and breast cancers express B7-H4 protein (9) , and B7-H4 expression in renal cell carcinoma (10) (11) (12) , melanoma (13) , breast (14) , lung (15, 16) , gastric (17) , colorectal (18) , pancreatic (19) , and prostate (20) cancer are associated with one or more clinicopathological factors, including tumor size, cancer stage, metastasis, progression, prognosis, survival, the intensity of tumor infiltrating T cells, the infiltration intensity of Tregs and tumor associated macrophages, disease recurrence or mortality.
Therefore, targeting B7-H4 may be an alternative strategy to reinvigorate tumor-specific T cell responses.
Urothelial carcinoma is the fifth most common cancer in the US and has the second worst survival for patients with metastasis at only 5% at years (21) . While systemic chemotherapy has been the standard of care for treatment of patients with metastatic urothelial carcinoma, in 2016 antibodies targeting immune checkpoint blockade (ICB), specifically PD1 and PDL1 were FDA approved (22) . However, only 21% of patients with metastatic urothelial carcinoma refractory to chemotherapy respond to anti-PD1 antibodies (23) . While the factors that determine clinical response are not completely known, features such as immune cell infiltration and high total mutation burden have been associated with an increased response (24) . Not all studies have demonstrated that PDL1 expression is associated with improved survival following anti-PD-1 therapy, suggesting that multiple aspects of the regulation of immune responses to tumor remain unclear (25) . Thus, most patients will progress and would benefit from additional therapies, targeting distinct, non-overlapping immune regulatory pathways.
Results

B7-H4 expression increases during bladder cancer development and is overexpressed in human bladder cancer
To investigate the interaction between bladder cancer initiation and progression we used the syngeneic, carcinogen-induced mouse model of bladder cancer derived from timed exposure to N-butyl-N-(4-hydroxybutyl)-nitrosamine (BBN). Our laboratory has previously validated the genomic credibility of this model that develops muscle-invasive bladder cancer (MIBC) between three and five months after initial exposure (37) . Evaluation of the mutation signature most closely aligns with those caused by smoking, justifying the clinical relevance of BBN to bladder cancer, in which over 60% of cancers are attributed to smoking carcinogens (38) . The BBN model of bladder cancer offers the distinct advantage that immune effector and regulatory processes can be assessed both in the bladder and peripheral immune organs from the initiation of tumorigenesis until the development of palpable tumors. Therefore, C57BL/6 (B6) mice were provided BBN and gene expression profiling was performed early (1, 2, and 4 weeks) after exposure to the carcinogen. We identified early expression of immune response-related genes that increased from low levels at one week to higher levels at two weeks of BBN exposure ( Figure   1A ). This included transcripts for CD8, CD4, and pathways associated with regulation of inflammation. For example, markers of T cell exhaustion (PD-L1, LAG-3 and Tim-3) and regulation (FoxP3 and Nrp-1) increased by 2 weeks, and B7-H4, a protein expressed by APCs that is known to inhibit T cell function via both direct and indirect mechanisms (4, 39) , was significantly increased by four weeks and corresponded to a decrease in CD8 and CD4 transcripts within the bladder ( Figure 1A ). To determine if B7-H4 could play a role in human bladder cancer, we evaluated the expression of B7-H4 in the cancer genome atlas for muscle invasive bladder cancer (MIBC). Patients with high expression of B7-H4 had significantly worse overall survival compared to those with lower expression (21.85 vs 34.03 months, p=0.03) ( Figure 1B ).
Additionally, enriched B7-H4 expression positively correlated with B cells, iDCs, and macrophage transcripts, however B7-H4 expression did not correlate with T cells and IFN-g levels present from MIBCs (29) (Supplemental Figure 1 ). Unlike other immune checkpoints (such as PD-L1, PD-L1, and CTLA-4), expression of B7-H4 does not appear to correlate with neoantigens, total mutation burden, APOBEC mutations or gene signatures (Supplemental Figure 2 ). We also found significant B7-H4 enrichment in bladder tumor subtypes that had relatively low expression of PD-L1, PD-1, and CTLA-4 including luminal, luminal papillary and luminal infiltrated tumors using the 2017 TCGA molecular subtyping classification ( Figure 1C ). Since expression of PD-L1 is directly associated with response to anti-PD-L1 and anti-PD-1 therapy, treatment of bladder cancer via blockade with a checkpoint inhibitor expressed in a different tumor subtype could lead to improved overall outcomes for patients. Thus, we were interested in the location of B7-H4 expression in bladder cancers, including localization of the tumor and tumor microenvironment. Using immunohistochemistry, we found expression of B7-H4 localized to immune cells resident in normal bladder, with increased expression in low and higher grade papillary tumors, respectively ( Figure 1D , Right, middle panels). Yet, using the BBN mouse carcinogen model, B7-H4 expression co-localized with CD11b + myeloid cells ( Figure 1D , left) only. This suggests that expression of B7-H4 was likely localized to the myeloid lineage only and not expressed by the tumors in the BBN mouse model. To confirm this localization, we performed single-cell RNA-Seq of a stage Ta high grade bladder tumor ( Figure 1E ). VTCN1 (B7H4) mRNA was detected on both urothelial cells (EPCAM+) and myeloid cells (CD68+) by scRNA sequencing. While VTCN1 was expressed ubiquitously throughout the urothelial clusters, myeloid VTCN1 was found on a subset of cells. Myeloid VTCN1 shows scattered expression across the myeloid cluster without restriction to any one particular subcluster. To futher confirm the cellular localization of B7-H4, we performed imaging mass cytometry, that demonstrated localization of B7-H4 to CD68+ myeloid cells.
Consistent with scRNA sequencing many CD68+ cells did not show expression of B7-H4 by imaging mass cytometry.
Temporal expression of PD-L1 and B7-H4 and their respective ligands in BBN-induced bladder cancer
Mice given BBN in drinking water, develop carcinoma in situ (CIS) by 2-3 months, and mice present with tumors by 3 months and bulky tumors by 4 months (40) . We next went on to validate the transcript data presented in Figure 1 Figure 2F ). There was a small peak of B7-H4 + monocytes at one month, followed by a decline, and a second peak concordant with tumor development and immune cell infiltration of bladder tumors at 5 months ( Figure 2I ). Additionally, the bi-phasic pattern of PD-L1 and B7-H4 expression correlated with both the numbers of CD4 + Treg ( Figure 2J ) and effector CD4 + T and CD8 + T cells ( Figure 2K and 2L). These findings confirm B7-H4 expression by bladder-infiltrating monocytes concordant with CD4 + and CD8 + TILs suggestive of induction of an anti-inflammatory regulatory mechanism. Based on these results, we investigated the blockade of B7-H4 as a potential therapy to increase T cell responses by blocking B7-H4-mediated T cell regulation.
Anti-B7-H4 blocks the immunoregulatory function of B7-H4Ig and increases mouse and human CD4 + and CD8 + T cell function
To functionally demonstrate that anti-B7-H4 can inhibit the regulatory function of B7-H4, we tested the ability of anti-B7-H4 to block the immunoregulatory function of human B7-H4Ig. SJL/J lymph node cells (5x10 5 cells/well) were labeled with CFSE, and stimulated with anti-CD3 (1µg/ml) plus control Ig, human B7-H4Ig, and/or anti-B7-H4 (10µg/ml) as indicated ( Figure 3A confirmed that anti-B7-H4 blocked the inhibitory function of human B7-H4Ig ( Figure 3A ). As a further confirmation of the ability of anti-B7-H4 to block hB7-H4Ig function, SJL/J mice were primed with PLP139-151/CFA, and treated 3 times per week for 2 weeks beginning at the time of priming (Day 0) with control Ig, hB7-H4Ig, or anti-B7-H4 as indicated. Mice were observed for paralytic disease symptoms. As we previously reported (4), hB7-H4Ig treatment significantly decreased disease severity ( Figure 3B ). While anti-B7-H4 treatment alone did not modulate the level of disease severity, treatment with anti-B7H4 blocked the hB7-H4Ig-induced decrease in disease severity ( Figure 3B ). In addition, anti-B7H4 blocked the hB7-H4Ig-induced decrease in in vivo CD4 + T cell function as measured by delayed-type hypersensitivity (DTH) responses to ear challenge with PLG139-151. Taken together, these findings show that anti-B7-H4 blocks hB7-
H4Ig-induced regulatory function on mouse T cell responses both in vitro and in vivo.
To determine if anti-B7-H4 could block B7-H4-induced regulation of human T cells, CD14 + monocytes from healthy donors were cultured for 3 days with IL-10, IL-6, and IL-10 plus IL-6 (10ng/ml). Adherent cells were collected and analyzed via flow cytometry. Upregulated expression of B7-H4, CD80, CD86, PD-L1, and PD-L2 expression was identified following stimulation with IL-10 and/or IL-6 ( Figure 4A ). Therefore, IL-10 + IL-6 stimulated CD14 + APCs were co-cultured with autologous CD4 + and CD8 + T cells in anti-CD3-coated wells + control Ig or anti-B7-H4 and proliferation and IFN-g production measured on 3 d thereafter. While addition of anti-B7-H4 did not significantly enhance proliferation of CD4 + ( Figure 4B ) or CD8 + T cells ( Figure   4D ), anti-B7-H4 induced a significant increase in production of IFN-g by both CD4 + and CD8 + T cells ( Figure 4C and 4E). Thus, anti-B7-H4 blockade increased the function of both human CD4 + and CD8 + T cells stimulated with B7-H4 expressing monocytes.
Anti-B7-H4 treatment increases CD8 + T cell infiltration into the bladder during BBNinduced bladder cancer and IFN-g production by splenic CD8 + T cells
After confirmation of the functional activity of our B7-H4 antibody, we tested its activity in the BBN carcinogen model of bladder cancer. Mice received BBN containing water for four months and received treatment with a species and isotype matched Control Ab, anti-PD-1, or anti-B7-H4 for once weekly for four total treatments. After treatment, animals were placed on normal drinking water for 30 days followed by tumor analysis ( Figure 5A ). Anti-B7-H4 treatment led to a decrease in the number of advanced tumors (70% compared to 50% stage 3 or greater), and a significant increase in the number of CD8 + bladder-infiltrating T cells ( Figure 5B , C). In contrast, anti-B7-H4 treatment decreased the number of FoxP3 + Tregs (Fig 5B,D) , indicating that anti-B7-H4 treatment had shifted the CD8 + T cell to Treg ratio in favor of an anti-tumor response. While treatment of mice with anti-PD-1 or anti-B7-H4 did not alter the number of total splenic CD45hi cells, CD4 + T cells, or CD8 + T cells ( Figure 5E ), both anti-PD-1 and anti-B7-H4 treatments significantly increased the number of CD8 + /IFN-g + cells present within the spleen compared to control IgGtreated mice ( Figure 5F ). Additionally, total splenocytes from the treatment groups were activated ex vivo in the presence of anti-CD3 for 3 days to assess levels of cytokine secretion. Significantly, splenocytes from anti-B7-H4-treated mice secreted significantly higher levels of IFN-g in response to anti-CD3 stimulation than did T cells from control IgG or anti-PD-1 treated mice ( Figure 5G ).
Taken together, these findings indicate that anti-B7-H4 treatment of BBN mice induced an increase in CD8 + T cell infiltration into tumors within the bladder and increased the level of IFN-g secreted per splenic CD8 + T cell.
We evaluated the gene expression profile of anti-B7H4 treated mice and found a re-establishment of normal gene expression associated with urothelium differentiation. These included increased expression of bladder muscle/detrusor-related pathways and urothelial differentiation (uroplakin 3b) and decreased expression of cell-cycle progression, mitosis, and cell cycle checkpoints (Supplemental Figure 3 ). Most prominent, response to B7-H4 was associated with decreased expression of oncogenes Hoxb9, H19 and Egln3. We also observed metabolic changes suggestive of aerobic pathways including Car2 (carbonic anhydrase), adh1 (alcohol dehydrogenase), and Pck1. Lastly, we showed that anti-B7H4 antibody therapy synergized with anti-PD1 therapy, the current standard of care for metastatic, and chemotherapy-resistant cancer, leading to a significant reduction in advanced tumors (40% increase in stage I tumors: 60% in combination treated mice compared to 20% in vehicle treated mice ( Figure 5H ) (p=0.017).
Discussion
Bladder cancer, similar to other solid tumors attributed to carcinogen exposure including lung cancer and melanoma, is driven by a high total mutation burden at approximately 7 mutations/MB (41) . Systemic immunotherapy has changed the survival of patients with bladder cancer for those unresponsive to cisplatin (CIS) chemotherapy, or unable to received chemotherapy with a median progression free survival of 10.3 months (95% confidence interval [CI], 8.0 to 11.8) compared with 7.4 months (95% CI, 6.1 to 8.3) in those treated with chemotherapy (hazard ratio for death, 0.73; 95% CI, 0.59 to 0.91; P=0.002) (23) . Recent application of anti-PD1 and anti-PDL1 therapy to the neoadjuvant setting have shown promising results to decrease pathologic stage and potentially improve recurrence free survival (42) . Yet, less than 20% of patients treated with checkpoint immunotherapy have a clinical response and even in those with MIBC, choosing the right systemic therapy prior to cystectomy remains critical to limit toxicity prior to resection. Until To identify potential immune regulatory mechanisms involved in the immune-editing of bladder cancer, we profiled the immune landscape of the mouse BBN bladder cancer model from 2 to 20 weeks. Our group has previously validated the genomic alterations that develop in this model (37) . To our knowledge, we are the first to describe the immune activation that is bi-modal after BBN treatment. The present data show that there is an acute inflammatory phase that starts within two weeks, but then decreases between four and twelve weeks. While we observed Across solid tumors, expression of B7-H4 is associated with worse survival (6) (7) (8) . High expression of B7-H4 has been described in ovarian, endometrial, gastric, renal cell, melanoma, breast, lung, colorectal, pancreatic, and prostate cancer. Mechanistic investigation of B7-H4 in liver cancer identified B7-H4 expression on tumor cells and antigen presenting cells of the liver that were coexpressed with PD-1 and Tim-3. Genetic targeting of B7-H4 resulted in increased proliferation of CD8 + T cells with decreased levels of exhaustion transcription factors (5) . In the current study, we confirmed increased CD8 + TIL activation induced by treatment with anti-B7-H4 antibody as a mechanism of immune activation. Additionally, we found lower numbers of FoxP3 + Tregs that can decrease the anti-tumor immune response.
In addition to effects on Tregs, receptor ligation by the immune modulatory molecules, such as B7-H4, have been suggested to directly alter the phenotype of CD4 + T cells (44, 45) . Co-culture of CD4 + T cells with IL-10/TGF-β treated macrophages expressing B7-H4 decreased CD4 + T cell proliferation and increased the number of FoxP3 + CD4 + T cells (46) . Published data show that hB7-H4Ig binds to CD4 + T cells in an activation-dependent manner, indicating that B7-H4 may function as a co-inhibitory (negative co-stimulatory) molecule for CD4 + T cells (4, 44, 47) . The present data show that B7-H4 also directly interacts with a functional B7-H4 receptor on CD8+ T cells, as the addition of anti-B7-H4 to monocyte/CD8 + T cell co-cultures induced a significant increase in the level of secreted IFN-g ( Figure 4E ). This is supported by our previous findings showing that hB7-H4Ig can down-regulate IL-17 and IFN-g production of mouse T cells in the absence of Tregs (4). Further, our in vivo data show that treatment of C57BL/6 mice with BBNinduced bladder cancer have a significant increase in the number of CD8 + T cells and a significant decrease in the number of Tregs present within the bladder ( Figure 5C and D) . This finding correlated with an increase in the percentage of IFN-g + /CD8 + T cells present within the spleen and a significant decrease in tumor stage as compare to Control Ab treated mice. While the present data have shown the functionality of anti-B7-H4 treatment in the presence of monocyte expressed B7-H4, B7-H4 expression by tumor cells is also a putative mechanism by which these cells evade anti-tumor immune responses. In the majority of breast and ovarian cancers, B7-H4 mRNA is expressed at approximately 2-fold or greater than the level expressed within normal tissue (48) , and B7-H4 protein is present in half of early stage and two-thirds of late stage ovarian tumors (49) . Additionally, tumor tissues from breast, uterus, ovary, colon, and pancreas showed a statistically significant increase in the percentage of cells expressing B7-H4 (50). In the 4T1 metastatic breast cancer model, transfer of tumor cells into B7-H4 -/vs. wildtype mice resulted in fewer lung nodules, enhanced survival, and decreased tumor infiltration of immunosuppressive cells (51) . Based on these findings expression of B7-H4 within the tumor microenvironment, either by the tumor cells and/or by infiltrating monocytes, is hypothesized to promote immune evasion. In support of this hypothesis, we showed that stimulation of the B7-H4 receptor complex via hB7-H4Ig treatment of mice during EAE increased the number and function of Tregs (4).
Our investigation identified B7-H4 as a negative regulator of T cell activity in the bladder during cancer development. The present data show that treatment of C57BL/6 male mice receiving BBN containing water with anti-B7H4 increases the number of CD8+ T cells and decreases the number of Tregs present within the bladder. The anti-B7-H4 treatment-induced skewing of the CD8 + T cell to Treg ratio within the bladder correlated with a decrease in the bladder cancer stage score.
Additionally, co-treatment of mice with both anti-B7-H4 and anti-PD1 further decreased bladder cancer stage score, and such combination therapy may be considered a target for future therapeutic trials in patients with bladder cancer.
Materials and Methods
Tumor Preparation for Single-Cell RNA-Seq
Tumor samples were obtained prospectively after IRB approval at Northwestern (STU00088853).
Tumor specimen was minced and enzymatically dissociated DMEM supplemented with Liberase TM (0.0625 mg/ml) and DNase I (Sigma, D5025, 0.2 mg/mL) for 30 minutes. Every 10 minutes specimen was gently pipetted and enzyme mix was exchanged for freshly made enzyme mix.
After dissociation tissue was spun down at 1300 RPM for 7 minutes and filtered to through a 100 um filter to yield a single cell suspension. Cells were spun down, resuspended in PBS supplemented with 0.5% BSA and 2 mmol/L EDTA and stained with PI (BD) and Calcein Violet 
Single-Cell Data Processing
The Cell Ranger pipeline (v1.2, 10X Genomics) was used to convert Illumina base call files to FASTQ files, align FASTQs to the GRCH38 reference (v3.0.0, 10X Genomics) for human samples to produce a digital gene-cell counts matrix. The resultant gene-cell matrix was filtered to remove cells with fewer than 500 transcripts and genes with fewer than two counts in two cells. The genecell matrices were then normalized such that the number of unique molecular identifiers (UMI) in each cell is equal to the median UMI count across the data set and log transformed. Expression at 1,000 highly variable genes in each data set, selected as the genes with the highest dispersion, was used to reduce the dimensionality of the data sets to three dimensions using Uniform Manifold Approximation and Projection (UMAP) and cells were clustered using Leiden based clustering in the UMAP space. Genes of interest were plotted in UMAP space using adjusted values based on Markov Affinity-based Graph Imputation (MAGIC) of the raw gene-cell counts matrix. At the end of treatment, animals were euthanized by CO2 with secondary cervical dislocation.
Multiplexed Imaging by IMC
Bladders were removed and divided in the sagittal plane, and either fixed in 10% formalin or snapfrozen in liquid nitrogen. Pathology was staged using human AJCC staging of degree of bladder wall invasion.
RNA extraction, Library Creation and RNA-Seq
Mouse tumors were ground using liquid nitrogen and a mortar and pestle, and then RNA was extracted using Trizol Reagent (Thermo Fisher Scientific) following manufacturer's instructions.
RNA quality and concentration were assessed by NanoDrop and then Qubit Fluorometric
Quantitation (Thermo Fisher Scientific). Library preparation and RNAseq were performed at the NuSeq core facility (Northwestern University) using an Illumina HiSeq 2000. 
Immunohistochemistry
PE
Bioinformatics
Clinical, mRNA seq, and mutation data from The Cancer Genome Atlas (TCGA) bladder urothelial carcinoma dataset was downloaded from the Broad Institute Genome Data Analysis Center (GDAC) using TCGA data version 2016_01_28 (http://gdac.broadinstitute.org) (26, 27) . Analysis was performed with R v3.5.1 utilizing Bioconductor v3.9. RNA-seq mRNA expression levels are presented as RNA-seq by expectation-maximization (RSEM) values, and z-score >2 was used to define overexpression (28) . Overall survival outcomes were calculated using the log-rank test and R packages survival v2.43-3 and survminer v0.4.3. Pan-cancer expression profile of B7-H4 (VTCN1) was extracted from the Broad GDAC Firehose v1.1.38 (http://firebrowse.org/). Spearman correlations between B7-H4, PD-1, PD-L1, and CTLA-4 expression and mutation, neoantigen, and APOBEC enrichment was performed using ggplot2 v3.1.0. Molecular subtypes (luminal, luminal-papillary, luminal-infiltrated, basal-squamous, and neuronal) were assigned as previously described (29) . Comparison of expression between subtypes was performed using Kruskal-Wallis ANOVA. Immune signatures were calculated as previously described (30) (31) (32) .
Hierarchical clustering of immune signatures in among molecular subtypes was performed with multiClust v1.4.0 and gplots v3.0.1 (33) . Correlation heatmap of immune signatures and B7-H4 expression was created using ggplot2 v3.1.0.
For murine tumors, following quality control and adapter trimming, reads were mapped to mm10 genome using STAR (34) , and then counted using HTSeq (35) . Gene counts were converted to CPM and further analyzed in R using the Bioconductor packages limma and edgeR. Limma was used to generate MDS plots and call differentially expressed (DE) genes. Top DE genes were visualized by Volcano plots, and used for Pathway Analysis that was conducted using the Bioconductor packages TopGO and ReactomePA (36) . The most significant pathways 
